Using biomarkers to predict prostate cancer biochemical relapse
نویسندگان
چکیده
The early detection of prostate cancer with prostatespecific antigen (PSA) testing allows many patients the option of radical treatment with curative intent. However, up to 30% of patients undergoing radical prostatectomy for clinically localized disease will experience biochemical relapse. In some cases, biochemical relapse represents micro-metastatic disease, undetectable before surgery and almost invariably still undetectable at the time of recurrence of PSA [1]. Pound et al. [2] suggested that an increase in PSA within 2 years of radical surgery indicates Abstract
منابع مشابه
Identification and Validation of Potential New Biomarkers for Prostate Cancer Diagnosis and Prognosis Using 2D-DIGE and MS
This study was designed to identify and validate potential new biomarkers for prostate cancer and to distinguish patients with and without biochemical relapse. Prostate tissue samples analyzed by 2D-DIGE (two-dimensional difference in gel electrophoresis) and mass spectrometry (MS) revealed downregulation of secernin-1 (P<0.044) in prostate cancer, while vinculin showed significant upregulation...
متن کاملValidation of the Prostate Cancer Risk Index (PRIX): a simple scoring system to predict risk of biochemical relapse after radical prostatectomy for prostate cancer.
OBJECTIVE The Prostate Cancer Risk Index (PRIX) is a simple scoring system for risk stratification of clinically localized prostate cancer that relies on three variables: prostate-specific antigen level at diagnosis, Gleason score at biopsy and clinical T stage. The aim of this study was validation of the ability of the PRIX score to predict biochemical relapse after radical prostatectomy in a ...
متن کاملmiRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression.
Prostate cancer is the leading cancer diagnosed and the second most common cause of cancer related death in the western world. For prognostic monitoring after prostatectomy, recurrent increase of prostate-specific antigen (PSA), the so-called PSA or biochemical relapse remains the leading biomarker. There is currently no biomarker that can accurately predict the risk of relapse at the time of s...
متن کاملHigh-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.
BACKGROUND Two clinical trials have shown that users of 5α-reductase inhibitors finasteride and dutasteride (5-ARIs) have reduced overall prostate cancer risk, while the proportion of high-grade tumors is increased. We studied tumor characteristics, risk of biochemical recurrence and mortality after radical prostatectomy in 5-ARI and alpha-blocker users. METHODS The study cohort consisted of ...
متن کاملAndrogen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.
Prostate cancer biology varies from locally confined tumors with low risk for relapse to tumors with high risk for progression even after radical prostatectomy. Currently, there are no reliable biomarkers to predict tumor relapse and poor clinical outcome. In this study, we correlated expression patterns of the androgen receptor (AR) coactivators lysine-specific histone demethylase 1 (LSD1) and...
متن کامل